Disclaimer

For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the  website.

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.

Decline
Eluvia banner image

A New Standard Of Care In SFA Stenting

Eluvia Drug-Eluting Stent Technology

Eluvia™ drug-eluting stent offers sustained drug release, with the lowest drug dose density, delivered by the most proven polymer

Next-generation technology

Eluvia banner image

Built for sustained drug release and efficient drug transfer.

Eluvia is designed to meet the challenges of the superior femoral artery (SFA) with outstanding flexibility and precise stent placement. Only the Eluvia™ drug-eluting stent (DET) offers sustained drug release to match the restenosis process in the SFA, with the lowest drug dose density1 delivered by the most proven polymer.

Polymer designed for controlled drug release

Eluvia has the lowest drug dose density1 (0.167 μg/mm2) delivered by the world’s most proven polymer. It ensures targeted delivery to the lesion and features the lowest systemic drug exposure for the patient among all peripheral paclitaxel-based technologies2.

EluviaInfographic showing TransPax is lipophilic and TransPax is hydrophobic.

Eluvia's downstream impact

downstream-vs-bare-metal-stent

Eluvia size matrix

eluvia-matrix-stent-length-data-d_emea

Triaxial delivery system

Built for more precise and predictable stent placement.

Innova self-expanding nitinol stent system for Superficial Femoral Artery (SFA)
Icon representing download resources

Receive downloads for clinical data sheets and additional resources for our Drug-Eluting Technologies.

Explore resources
Icon representing get updates

Stay up to date with the latest DET news and events in your area.
 

Register

Footnotes

*Drug Dose Data from Eluvia DES, Zilver BIX DES, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use.
**Kaplan-Meier Estimate. 1-Year Results published in The Lancet. https://doi.org/10.1016/S0140-6736(18)32262-1.
***Data on file at Boston Scientific. Devices were tested in simulated use conditions in a tortuous vessel model under clinically relevant flow conditions. Downstream particulates collected with a polycarbonate filter. 
****The limit of quantification was defined as 1 ng/mL. IMPERIAL PK Substudy. IMPERIAL 1-Year Results published in the Lancet. https://doi.org/10.1016/S0140-6736(18)32262-1.

References

1. Data from Eluvia, Lutonix, Stellarex, Zilver PTX and IN.PACT Directions for Use. 
2. Drug Dose Data from Eluvia DES, Zilver PTX, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use. Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.